Navigation path

Community Register of medicinal products

Community register of orphan medicinal products


GRANTED  

Product information

Olaparib

EU orphan designation number: EU/3/07/501   
Active ingredient: Olaparib
Indication: Treatment of ovarian cancer
Sponsor: AstraZeneca AB
Forskargatan 18, SE-151 85 Södertälje, Sverige

   Public summary of scientific opinion    

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
10/12/2007 Centralised Orphan - Designation EMEA/OD/063/07 (2007)6258 of 06/12/2007